Project description
Prevention of ischaemic injury in kidney transplants
Donor kidneys lack natural blood flow while awaiting transplantation, potentially resulting in tissue ischemia. After transplantation and connection to the recipient’s blood flow, this may lead to ischemia-reperfusion injury (IRI). Preventing IRI is one of the top priorities for the transplantation community, and Corline Biomedical in Sweden has developed the pharmaceutical compound Renaparin® for coating the lining of the kidney blood vessels before transplantation. Preliminary data have demonstrated the drug’s potential to improve the success of kidney transplantation. The EU-funded Renaparin project aims to carry out phase I/IIa clinical trials in humans to obtain clinical safety and preliminary clinical efficacy data, enabling further clinical development and commercialisation of the product.
Objective
This project will validate the safety and efficacy of Corline Biomedical’s pharmaceutical compound Renaparin®, a novel cell replacement technology used to coat the lining of the blood vessels of kidneys prior to transplantation.
Donor kidneys lack natural blood flow while awaiting transplantation. This can lead to ischemia (a shortage of oxygen and glucose supply to the kidney tissue). When connected to the recipient’s blood flow, this in turn leads to ischemia reperfusion injury (IRI).
Given the alarming shortage of organs available for transplantation in the EU and internationally, the prevention of IRI has become a top priority for the transplantation community. Transplantation surgeons and nephrologists emphasise the pressing need for safe and effective technologies which can improve the outcome of kidney transplantation and extend donor criteria.
Renaparin® is used when the kidney has been extracted from the donor and is stored in preservation solution awaiting transplantation. There, it binds to, replaces, repairs and protects damaged kidney cells on the endothelium of the vascular wall. As a result, a kidney is less likely to activate the host’s innate immune system, which increases the chances of organ survival and substantially reduces the likelihood of organ rejection.
The research performed in preparation of further development of Renaparin® strongly supports the drug’s potential to increase the success of kidney transplantation. The activities proposed in this project will bring Renaparin® through a Phase I/IIa clinical trial in humans. The produced clinical safety data and preliminary clinical efficacy data will constitute the basis for further clinical development and commercialisation of the product.
Corline’s strategic focus lies on establishing Renaparin® as a new cell replacement technology in kidney transplantation. This will constitute the cornerstone of Corline’s accelerated growth. The project is the key step to realize this strategy.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- medical and health sciences basic medicine pharmacology and pharmacy pharmaceutical drugs
- medical and health sciences clinical medicine nephrology
- medical and health sciences basic medicine immunology
- medical and health sciences clinical medicine transplantation
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being
MAIN PROGRAMME
See all projects funded under this programme -
H2020-EU.3.1.3. - Treating and managing disease
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
SME-2 - SME instrument phase 2
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) H2020-SMEInst-2016-2017
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
754 50 UPPSALA
Sweden
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.